Abstract
Bayer is a global enterprise, headquartered in Germany, with core competencies
in the fields of healthcare, nutrition and high-tech materials. This report
provides a full review of the company' s activities together with sales
forecasts for key products to 2010.
Bayer is a global enterprise, headquartered in Germany, with core competencies
in the fields of healthcare, nutrition and high-tech materials. It currently
ranks 15th among research-based pharmaceutical companies in terms of pharma
sales and annually invests about 7.1 per cent of its total sales in research
and development, ranking 74th compared to other pharmaceutical companies.
Oncology and cardiovascular risk management, including diabetes, are the main
areas of Bayer' s future strategic focus within pharmaceuticals.
Current Growth Drivers
With successful life-cycle management, the established products Levitra,
Kogenate, Trasylol and Avalox continue to drive sales.
Key Late-Phase Products Reaching the Market Place
Nexavar was launched for renal cell carcinoma in the US in December 2005, and
an EU launch is expected in the second half of 2006. A Phase III trial in
hepatocellular carcinoma started in March 2005, is now completed.
Key Late-Stage Products
BAY 59-7939, an oral, direct inhibitor of Factor Xa, is currently in Phase III
development for venous thromboembolism (VTE) prevention after major
orthopaedic surgery has been initiated. The product is on schedule for
regulatory filing in late 2007.
| 
View Cart
